OUR LATEST NEWS
December 4, 2023
OXFORD BIOMEDICA SIGNS AGREEMENT TO ACQUIRE ABL EUROPE FROM INSTITUT MERIEUX
October 24, 2023
HOW TO CHOOSE THE RIGHT CDMO PARTNER
October 19, 2023
KEY CMC CONSIDERATIONS FOR THE DEVELOPMENT OF YOUR VIRUS / VIRAL-VECTOR PROGRAMS
October 5, 2023
UNLOCKING SUCCESS IN GENE THERAPIES: THE CRUCIAL ROLE OF QTPP AND FINDING THE RIGHT PARTNER TO DEPLOY THE QBD APPROACH
September 21, 2023
OXFORD BIOMEDICA AND INSTITUT MERIEUX ENTER INTO EXCLUSIVE NEGOTIATIONS FOR THE PROPOSED ACQUISITION OF ABL EUROPE
September 18, 2023
ASEPTIC PROCESS OF VIRAL VECTOR-BASED VACCINES – KEY ASPECTS TO CONSIDER BEFORE CLINICAL MANUFACTURING
August 29, 2023
PROCESS CHARACTERIZATION OF VIRAL VECTORS: APPROACH IN CDMO CONTEXT
October 25, 2022
ABL AND RD-BIOTECH SIGN STRATEGIC PARTNERSHIP IN CELL AND GENE THERAPY GMP MANUFACTURING
October 18, 2022
ABL AND IMUGENE PARTNER TO ADVANCE ONCOLYTIC VIRUS CANDIDATE TOWARDS LATER PHASE CLINICAL TRIALS
July 11, 2022